[1]
|
K. Takehara, Y. Soma and Y. Ishibashi, “Early Detection of Scleroderma Spectrum Disorders in Patients with Raynaud’s Phenomenon,” Dermatologica, Vol. 183, No. 3, 1991, pp. 164-168. doi:10.1159/000247662
|
[2]
|
P. Youssef, T. Brama, H. Englert and J. Bertouch, “Limited Scleroderma Is Associated with Increased Prevalence of Macro Vascular Disease,” The Journal of Rheumatology, Vol. 22, No. 3, 1995, pp. 469-472.
|
[3]
|
M. Stücker, S. Quinna, U. Memmel, A. R?chling, M. Traupe, K. Hoffmann, et al., “Macroangiopathy of the Upper Extremities in Progressive Systemic Sclerosis,” European Journal of Medical Research, Vol. 5, No. 7, 2000, pp. 295-302.
|
[4]
|
M. Hasegawa, Y. Nagai, A. Tamura and O. Ishikawa, “Arteriographic Evaluation of Vascular Changes of the Extremities in Patients with Systemic Sclerosis,” British Journal of Dermatology, Vol. 155, No. 6, 2006, pp. 1159-1164. doi:10.1111/j.1365-2133.2006.07475.x
|
[5]
|
L. Dabich, J. J. Bookstein, A. Zweifler and C. J. Zarafonetis, “Digital Arteries in Patients with Scleroderma: Arteriographic and Plethysmographic Study,” Archives of Internal Medicine, Vol. 130, No. 5, 1972, pp. 708-714. doi:10.1001/archinte.1972.03650050036006
|
[6]
|
B. Janevski, “Arteries of the Hand in Patients with Scleroderma,” Diagnostic Imaging in Clinical Medicine, Vol. 55, No. 4-5, 1986, pp. 262-265.
|
[7]
|
G. N. Anderson, L. Mincheva-Nilsson, E. Kazzam, G. Nyberg, N. Klintland, A. S. Petersson, et al., “Assessment of Vascular Function in Systemic Sclerosis: Indications of the Development of Nitrate Tolerance as a Result of Enhanced Endothelial Nitric Oxide Production,” Arthritis and Rheumatism, Vol. 46, No. 5, 2002, pp. 1324-1332. doi:10.1002/art.10191
|
[8]
|
A. Cypiene, A. Laucevicius, A. Venalis, J. Dadoniene, L. Ryliskyte, Z. Petrulioniene, et al., “The Impact of Systemic Sclerosis on Arterial Wall Stiffness Parameters and Endothelial Function,” Clinical Rheumatology, Vol. 27, No. 12, 2008, pp. 1517-1522. doi:10.1007/s10067-008-0958-1
|
[9]
|
M. Ho, D. Veale, C. Eastmond, G. Nuki and J. Belch, “Macrovascular Disease and Systemic Sclerosis,” Annals of Rheumatic Diseases, Vol. 59, No. 1, 2000, pp. 39-43. doi:10.1136/ard.59.1.39
|
[10]
|
M. B. Hill, J. L. Phipps, R. J. Cartwright, et al., “Anti-bodies to Membranes of Endothelial Cells and Fibroblasts in Scleroderma,” Clinical and Experimental Immunology, Vol. 106, No. 3, 1996, pp. 491-497. doi:10.1046/j.1365-2249.1996.d01-867.x
|
[11]
|
D. Abraham, O. Distler, et al., “How Does Endothelial Cell Injury Start? The Role of Endothelin in Systemic Sclerosis,” Arthritis Research and Therapy, Vol. 9, Suppl. 2, 2007, p. S2. doi:10.1186/ar2186
|
[12]
|
S. Guiducci, O. Distler, et al., “Mechanisms of Vascular Damage in SSc—Implications for Vascular Treatment Strategies,” Rheumatology, Vol. 47, 2008, pp. 18-20. doi:10.1093/rheumatology/ken267
|